Characterization of HIV-2 chimeric viruses unable to use CCR5 and CXCR4 coreceptors

Virus Research

Volumn 142, Issue 1-2, 2009, Pages 41-50

  Santos Costa, Q ^a   Mansinho, K ^b   Moniz Pereira, J ^a   Azevedo Pereira, J M ^a  

^a RESEARCH INSTITUTE FOR MEDICINES IMED ULISBOA   (Portugal)

^b HOSPITAL EGAS MONIZ   (Portugal)

Author keywords

CCR5 independent; Chemokine receptors; CXCR4 independent; env gene; HIV 2; Molecular determinants; Replication kinetics; SU glycoprotein; TM glycoprotein

Indexed keywords

CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; GLYCOPROTEIN; PHYTOHEMAGGLUTININ; SURFACE GLYCOPROTEIN; TRANSMEMBRANE GLYCOPROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CHIMERA; ENVELOPE GENE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 2; NONHUMAN; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; VIRUS ENTRY; VIRUS RECOMBINANT; VIRUS REPLICATION;

CELL LINE; CELLS, CULTURED; CHIMERA; GENE PRODUCTS, ENV; HIV INFECTIONS; HIV-2; HUMANS; LEUKOCYTES, MONONUCLEAR; PROTEIN BINDING; RECEPTORS, CCR5; RECEPTORS, CXCR4; VIRUS INTERNALIZATION;

HUMAN IMMUNODEFICIENCY VIRUS 2;

EID: 67349225430     PISSN: 01681702     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.virusres.2009.01.012     Document Type: Article

References (96)

1. Abada P., Noble B., and Cannon P.M. Functional domains within the human immunodeficiency virus type 2 envelope protein required to enhance virus production. J. Virol. 79 (2005) 3627-3638
2. Albert J., Naucler A., Bottiger B., Broliden P.A., Albino P., Ouattara S.A., Bjorkegren C., Valentin A., Biberfeld G., and Fenyo E.M. Replicative capacity of HIV-2, like HIV-1, correlates with severity of immunodeficiency. AIDS 4 (1990) 291-295
3. Ancelle R., Bletry O., Baglin A.C., Brun-Vezinet F., Rey M.A., and Godeau P. Long incubation period for HIV-2 infection. Lancet 1 (1987) 688-689
4. Arthos J., Rubbert A., Rabin R.L., Cicala C., Machado E., Wildt K., Hanbach M., Steenbeke T.D., Swofford R., Farber J.M., and Fauci A.S. CCR5 signal transduction in macrophages by human immunodeficiency virus and simian immunodeficiency virus envelopes. J. Virol. 74 (2000) 6418-6424
5. Asjo B., Morfeldt-Manson L., Albert J., Biberfeld G., Karlsson A., Lidman K., and Fenyo E.M. Replicative capacity of human immunodeficiency virus from patients with varying severity of HIV infection. Lancet 2 (1986) 660-662
6. Azevedo-Pereira J.M., Santos-Costa Q., Mansinho K., and Moniz-Pereira J. Identification and characterization of HIV-2 strains obtained from asymptomatic patients that do not use CCR5 or CXCR4 coreceptors. Virology 313 (2003) 136-146
7. Azevedo-Pereira J.M., Santos-Costa Q., and Moniz-Pereira J. HIV-2 infection and chemokine receptors usage-clues to reduced virulence of HIV-2. Curr. HIV Res. 3 (2005) 3-16
8. Azevedo-Pereira J.M., Santos-Costa Q., Taveira N., Verissimo F., and Moniz-Pereira J. Construction and characterization of CD4-independent infectious recombinant HIV-2 molecular clones. Virus Res. 97 (2003) 159-163
9. Baba M., Nishimura O., Kanzaki N., Okamoto M., Sawada H., Iizawa Y., Shiraishi M., Aramaki Y., Okonogi K., Ogawa Y., Meguro K., and Fujino M. A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 5698-5703
10. Barnett S.W., Legg H.S., Sun Y., Klinger J., Blackbourn D.J., Locher C.P., and Levy J.A. Molecular cloning of the human immunodeficiency virus subtype 2 strain HIV-2UC2. Virology 222 (1996) 257-261
11. Berger E.A., Doms R.W., Fenyo E.M., Korber B.T., Littman D.R., Moore J.P., Sattentau Q.J., Schuitemaker H., Sodroski J., and Weiss R.A. A new classification for HIV-1. Nature 391 (1998) 240
12. Berger E.A., Murphy P.M., and Farber J.M. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu. Rev. Immunol. 17 (1999) 657-700
13. Bjorndal A., Deng H., Jansson M., Fiore J.R., Colognesi C., Karlsson A., Albert J., Scarlatti G., Littman D.R., and Fenyo E.M. Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype. J. Virol. 71 (1997) 7478-7487
14. Blaak H., Brouwer M., Ran L.J., de Wolf F., and Schuitemaker H. In vitro replication kinetics of human immunodeficiency virus type 1 (HIV-1) variants in relation to virus load in long-term survivors of HIV-1 infection. J. Infect. Dis. 177 (1998) 600-610
15. Blaak H., van der Ende M.E., Boers P.H., Schuitemaker H., and Osterhaus A.D. In vitro replication capacity of HIV-2 variants from long-term aviremic individuals. Virology 353 (2006) 144-154
16. Bour S.P., Aberham C., Perrin C., and Strebel K. Lack of effect of cytoplasmic tail truncations on human immunodeficiency virus type 2 ROD env particle release activity. J. Virol. 73 (1999) 778-782
17. Bour S.P., Schubert U., Peden K., and Strebel K. The envelope glycoprotein of human immunodeficiency virus type 2 enhances viral particle release: a Vpu-like factor?. J. Virol. 70 (1996) 820-829
18. Broder C.C., and Jones-Trower A. Coreceptor use by primate Lentiviruses. Human retroviruses and AIDS: a compilation and analysis of nucleic acid and amino acid sequences. In: Kuiken C., Foley B.T., Hahn B., Korber B., McCutchan F., Marx P.A., Mellors J.W., Mullins J.I., Sodroski J., and Wolinsky S. (Eds). Theoretical Biology and Biophysics Group (1999), Los Alamos National Laboratory, Los Alamos, NM 517-541
19. Bron R., Klasse P.J., Wilkinson D., Clapham P.R., Pelchen-Matthews A., Power C., Wells T.N., Kim J., Peiper S.C., Hoxie J.A., and Marsh M. Promiscuous use of CC and CXC chemokine receptors in cell-to-cell fusion mediated by a human immunodeficiency virus type 2 envelope protein. J. Virol. 71 (1997) 8405-8415
20. Bukrinskaya A., Brichacek B., Mann A., and Stevenson M. Establishment of a functional human immunodeficiency virus type 1 (HIV-1) reverse transcription complex involves the cytoskeleton. J. Exp. Med. 188 (1998) 2113-2125
21. Campbell T.B., Schneider K., Wrin T., Petropoulos C.J., and Connick E. Relationship between in vitro human immunodeficiency virus type 1 replication rate and virus load in plasma. J. Virol. 77 (2003) 12105-12112
22. Castro B.A., Barnett S.W., Evans L.A., Moreau J., Odehouri K., and Levy J.A. Biologic heterogeneity of human immunodeficiency virus type 2 (HIV-2) strains. Virology 178 (1990) 527-534
23. Chackerian B., Long E.M., Luciw P.A., and Overbaugh J. Human immunodeficiency virus type 1 coreceptors participate in postentry stages in the virus replication cycle and function in simian immunodeficiency virus infection. J. Virol. 71 (1997) 3932-3939
24. Cho M.W., Lee M.K., Carney M.C., Berson J.F., Doms R.W., and Martin M.A. Identification of determinants on a dualtropic human immunodeficiency virus type 1 envelope glycoprotein that confer usage of CXCR4. J. Virol. 72 (1998) 2509-2515
25. Cicala C., Arthos J., Ruiz M., Vaccarezza M., Rubbert A., Riva A., Wildt K., Cohen O., and Fauci A.S. Induction of phosphorylation and intracellular association of CC chemokine receptor 5 and focal adhesion kinase in primary human CD4+ T cells by macrophage-tropic HIV envelope. J. Immunol. 163 (1999) 420-426
26. Clapham P.R., and McKnight A. Cell surface receptors, virus entry and tropism of primate lentiviruses. J. Gen. Virol. 83 (2002) 1809-1829
27. Clavel F., Guetard D., Brun-Vezinet F., Chamaret S., Rey M.A., Santos-Ferreira M.O., Laurent A.G., Dauguet C., Katlama C., and Rouzioux C. Isolation of a new human retrovirus from West African patients with AIDS. Science 233 (1986) 343-346
28. Connor R.I., and Ho D.D. Human immunodeficiency virus type 1 variants with increased replicative capacity develop during the asymptomatic stage before disease progression. J. Virol. 68 (1994) 4400-4408
29. Davis C.B., Dikic I., Unutmaz D., Hill C.M., Arthos J., Siani M.A., Thompson D.A., Schlessinger J., and Littman D.R. Signal transduction due to HIV-1 envelope interactions with chemokine receptors CXCR4 or CCR5. J. Exp. Med. 186 (1997) 1793-1798
30. De Jong J.J., De Ronde A., Keulen W., Tersmette M., and Goudsmit J. Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium-inducing phenotype: analysis by single amino acid substitution. J. Virol. 66 (1992) 6777-6780
31. De Jong J.J., Goudsmit J., Keulen W., Klaver B., Krone W., Tersmette M., and de Ronde A. Human immunodeficiency virus type 1 clones chimeric for the envelope V3 domain differ in syncytium formation and replication capacity. J. Virol. 66 (1992) 757-765
32. Dean M., Carrington M., Winkler C., Huttley G.A., Smith M.W., Allikmets R., Goedert J.J., Buchbinder S.P., Vittinghoff E., Gomperts E., Donfield S., Vlahov D., Kaslow R., Saah A., Rinaldo C., Detels R., and O'Brien S.J. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 273 (1996) 1856-1862
33. Del Corno M., Liu Q.H., Schols D., de Clercq E., Gessani S., Freedman B.D., and Collman R.G. HIV-1 gp120 and chemokine activation of Pyk2 and mitogen-activated protein kinases in primary macrophages mediated by calcium-dependent, pertussis toxin-insensitive chemokine receptor signaling. Blood 98 (2001) 2909-2916
34. Dikic I., Tokiwa G., Lev S., Courtneidge S.A., and Schlessinger J. A role for Pyk2 and Src in linking G-protein-coupled receptors with MAP kinase activation. Nature 383 (1996) 547-550
35. Dragic T., Trkola A., Thompson D.A., Cormier E.G., Kajumo F.A., Maxwell E., Lin S.W., Ying W., Smith S.O., Sakmar T.P., and Moore J.P. A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 5639-5644
36. Dumonceaux J., Goujon C., Joliot V., Briand P., and Hazan U. Determination of essential amino acids involved in the CD4-independent tropism of the X4 human immunodeficiency virus type 1 m7NDK isolate: role of potential N glycosylations in the C2 and V3 regions of gp120. J. Virol. 75 (2001) 5425-5428
37. Dumonceaux J., Nisole S., Chanel C., Quivet L., Amara A., Baleux F., Briand P., and Hazan U. Spontaneous mutations in the env gene of the human immunodeficiency virus type 1 NDK isolate are associated with a CD4-independent entry phenotype. J. Virol. 72 (1998) 512-519
38. Eisenberg D., and Wesson M. The most highly amphiphilic alpha-helices include two amino acid segments in human immunodeficiency virus glycoprotein 41. Biopolymers 29 (1990) 171-177
39. Endres M.J., Clapham P.R., Marsh M., Ahuja M., Turner J.D., McKnight A., Thomas J.F., Stoebenau-Haggarty B., Choe S., Vance P.J., Wells T.N., Power C.A., Sutterwala S.S., Doms R.W., Landau N.R., and Hoxie J.A. CD4-independent infection by HIV-2 is mediated by fusin/CXCR4. Cell 87 (1996) 745-756
40. Gartner S., Markovits P., Markovitz D.M., Kaplan M.H., Gallo R.C., and Popovic M. The role of mononuclear phagocytes in HTLV-III/LAV infection. Science 233 (1986) 215-219
41. Gomes P., Taveira N.C., Pereira J.M., Antunes F., Ferreira M.O., and Lourenco M.H. Quantitation of human immunodeficiency virus type 2 DNA in peripheral blood mononuclear cells by using a quantitative-competitive PCR assay. J. Clin. Microbiol. 37 (1999) 453-456
42. Guillon C., van der Ende M.E., Boers P.H., Gruters R.A., Schutten M., and Osterhaus A.D. Coreceptor usage of human immunodeficiency virus type 2 primary isolates and biological clones is broad and does not correlate with their syncytium-inducing capacities. J. Virol. 72 (1998) 6260-6263
43. Hoffman T.L., and Doms R.W. HIV-1 envelope determinants for cell tropism and chemokine receptor use. Mol. Membr. Biol. 16 (1999) 57-65
44. Hoffman T.L., LaBranche C.C., Zhang W., Canziani G., Robinson J., Chaiken I., Hoxie J.A., and Doms R.W. Stable exposure of the coreceptor-binding site in a CD4-independent HIV-1 envelope protein. Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 6359-6364
45. Hoffman T.L., Stephens E.B., Narayan O., and Doms R.W. HIV type I envelope determinants for use of the CCR2b, CCR3, STRL33, and APJ coreceptors. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 11360-11365
46. Hu Q., Trent J.O., Tomaras G.D., Wang Z., Murray J.L., Conolly S.M., Navenot J.M., Barry A.P., Greenberg M.L., and Peiper S.C. Identification of ENV determinants in V3 that influence the molecular anatomy of CCR5 utilization. J. Mol. Biol. 302 (2000) 359-375
47. Iida S., Fukumori T., Oshima Y., Akari H., Koyama A.H., and Adachi A. Compatibility of Vpu-like activity in the four groups of primate immunodeficiency viruses. Virus Genes 18 (1999) 183-187
48. Iyengar S., Hildreth J.E., and Schwartz D.H. Actin-dependent receptor colocalization required for human immunodeficiency virus entry into host cells. J. Virol. 72 (1998) 5251-5255
49. Jaffar S., Wilkins A., Ngom P.T., Sabally S., Corrah T., Bangali J.E., Rolfe M., and Whittle H.C. Rate of decline of percentage CD4+ cells is faster in HIV-1 than in HIV-2 infection. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 16 (1997) 327-332
50. Kuhmann S.E., Platt E.J., Kozak S.L., and Kabat D. Cooperation of multiple CCR5 coreceptors is required for infections by human immunodeficiency virus type 1. J. Virol. 74 (2000) 7005-7015
51. Layne S.P., Merges M.J., Dembo M., Spouge J.L., and Nara P.L. HIV requires multiple gp120 molecules for CD4-mediated infection. Nature 346 (1990) 277-279
52. Lee C., Liu Q.H., Tomkowicz B., Yi Y., Freedman B.D., and Collman R.G. Macrophage activation through CCR5- and CXCR4-mediated gp120-elicited signaling pathways. J. Leukoc. Biol. 74 (2003) 676-682
53. Lev S., Moreno H., Martinez R., Canoll P., Peles E., Musacchio J.M., Plowman G.D., Rudy B., and Schlessinger J. Protein tyrosine kinase PYK2 involved in Ca(2+)-induced regulation of ion channel and MAP kinase functions. Nature 376 (1995) 737-745
54. Liu Q.H., Williams D.A., McManus C., Baribaud F., Doms R.W., Schols D., De Clercq E., Kotlikoff M.I., Collman R.G., and Freedman B.D. HIV-1 gp120 and chemokines activate ion channels in primary macrophages through CCR5 and CXCR4 stimulation. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 4832-4837
55. Liu R., Paxton W.A., Choe S., Ceradini D., Martin S.R., Horuk R., MacDonald M.E., Stuhlmann H., Koup R.A., and Landau N.R. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 86 (1996) 367-377
56. Long E.M., Rainwater S.M., Lavreys L., Mandaliya K., and Overbaugh J. HIV type 1 variants transmitted to women in Kenya require the CCR5 coreceptor for entry, regardless of the genetic complexity of the infecting virus. AIDS Res. Hum. Retroviruses % 20 18 (2002) 567-576
57. Maldarelli F., Chen M.Y., Willey R.L., and Strebel K. Human immunodeficiency virus type 1 Vpu protein is an oligomeric type I integral membrane protein. J. Virol. 67 (1993) 5056-5061
58. Marlink R., Kanki P., Thior I., Travers K., Eisen G., Siby T., Traore I., Hsieh C.C., Dia M.C., and Gueye E.H. Reduced rate of disease development after HIV-2 infection as compared to HIV-1. Science 265 (1994) 1587-1590
59. McKnight A., Dittmar M.T., Moniz-Periera J., Ariyoshi K., Reeves J.D., Hibbitts S., Whitby D., Aarons E., Proudfoot A.E., Whittle H., and Clapham P.R. A broad range of chemokine receptors are used by primary isolates of human immunodeficiency virus type 2 as coreceptors with CD4. J. Virol. 72 (1998) 4065-4071
60. Misse D., Cerutti M., Noraz N., Jourdan P., Favero J., Devauchelle G., Yssel H., Taylor N., and Veas F. A CD4-independent interaction of human immunodeficiency virus-1 gp120 with CXCR4 induces their cointernalization, cell signaling, and T-cell chemotaxis. Blood 93 (1999) 2454-2462
61. Mori K., Ringler D.J., and Desrosiers R.C. Restricted replication of simian immunodeficiency virus strain 239 in macrophages is determined by env but is not due to restricted entry. J. Virol. 67 (1993) 2807-2814
62. Morner A., Bjorndal A., Albert J., Kewalramani V.N., Littman D.R., Inoue R., Thorstensson R., Fenyo E.M., and Bjorling E. Primary human immunodeficiency virus type 2 (HIV-2) isolates, like HIV-1 isolates, frequently use CCR5 but show promiscuity in coreceptor usage. J. Virol. 73 (1999) 2343-2349
63. Mummidi S., Ahuja S.S., Gonzalez E., Anderson S.A., Santiago E.N., Stephan K.T., Craig F.E., O'Connell P., Tryon V., Clark R.A., Dolan M.J., and Ahuja S.K. Genealogy of the CCR5 locus and chemokine system gene variants associated with altered rates of HIV-1 disease progression. Nat. Med. 4 (1998) 786-793
64. Murphy P.M. Chemokine receptors: structure, function and role in microbial pathogenesis. Cytokine Growth Factor Rev. 7 (1996) 47-64
65. Noble B., Abada P., Nunez-Iglesias J., and Cannon P.M. Recruitment of the adaptor protein 2 complex by the human immunodeficiency virus type 2 envelope protein is necessary for high levels of virus release. J. Virol. 80 (2006) 2924-2932
66. O'Doherty U., Swiggard W.J., and Malim M.H. Human immunodeficiency virus type 1 spinoculation enhances infection through virus binding. J. Virol. 74 (2000) 10074-10080
67. Owen S.M., Ellenberger D., Rayfield M., Wiktor S., Michel P., Grieco M.H., Gao F., Hahn B.H., and Lal R.B. Genetically divergent strains of human immunodeficiency virus type 2 use multiple coreceptors for viral entry. J. Virol. 72 (1998) 5425-5432
68. Pepin J., Morgan G., Dunn D., Gevao S., Mendy M., Gaye I., Scollen N., Tedder R., and Whittle H. HIV-2-induced immunosuppression among asymptomatic West African prostitutes: evidence that HIV-2 is pathogenic, but less so than HIV-1. AIDS 5 (1991) 1165-1172
69. Pollakis G., Kang S., Kliphuis A., Chalaby M.I., Goudsmit J., and Paxton W.A. N-linked glycosylation of the HIV type-1 gp120 envelope glycoprotein as a major determinant of CCR5 and CXCR4 coreceptor utilization. J. Biol. Chem. 276 (2001) 13433-13441
70. Popik W., and Pitha P.M. Exploitation of cellular signaling by HIV-1: unwelcome guests with master keys that signal their entry. Virology 276 (2000) 1-6
71. Popper S.J., Sarr A.D., Gueye-Ndiaye A., Mboup S., Essex M.E., and Kanki P.J. Low plasma human immunodeficiency virus type 2 viral load is independent of proviral load: low virus production in vivo. J. Virol. 74 (2000) 1554-1557
72. Popper S.J., Sarr A.D., Travers K.U., Gueye-Ndiaye A., Mboup S., Essex M.E., and Kanki P.J. Lower human immunodeficiency virus (HIV) type 2 viral load reflects the difference in pathogenicity of HIV-1 and HIV-2. J. Infect. Dis. 180 (1999) 1116-1121
73. Poulsen A.G., Aaby P., Larsen O., Jensen H., Naucler A., Lisse I.M., Christiansen C.B., Dias F., and Melbye M. 9-year HIV-2-associated mortality in an urban community in Bissau, west Africa. Lancet 349 (1997) 911-914
74. Quinones-Mateu M.E., Ball S.C., Marozsan A.J., Torre V.S., Albright J.L., Vanham G., van Der Groen G., Colebunders R.L., and Arts E.J. A dual infection/competition assay shows a correlation between ex vivo human immunodeficiency virus type 1 fitness and disease progression. J. Virol. 74 (2000) 9222-9233
75. Reeves J.D., and Doms R.W. Human immunodeficiency virus type 2. J. Gen. Virol. 83 (2002) 1253-1265
76. Reeves J.D., Hibbitts S., Simmons G., McKnight A., Azevedo-Pereira J.M., Moniz-Pereira J., and Clapham P.R. Primary human immunodeficiency virus type 2 (HIV-2) isolates infect CD4-negative cells via CCR5 and CXCR4: comparison with HIV-1 and simian immunodeficiency virus and relevance to cell tropism in vivo. J. Virol. 73 (1999) 7795-7804
77. Reeves J.D., McKnight A., Potempa S., Simmons G., Gray P.W., Power C.A., Wells T., Weiss R.A., and Talbot S.J. CD4-independent infection by HIV-2 (ROD/B): use of the 7-transmembrane receptors CXCR-4, CCR-3, and V28 for entry. Virology 231 (1997) 130-134
78. Reeves J.D., and Schulz T.F. The CD4-independent tropism of human immunodeficiency virus type 2 involves several regions of the envelope protein and correlates with a reduced activation threshold for envelope-mediated fusion. J. Virol. 71 (1997) 1453-1465
79. Rey M.A., Laurent A.G., McClure J., Krust B., Montagnier L., and Hovanessian A.G. Transmembrane envelope glycoproteins of human immunodeficiency virus type 2 and simian immunodeficiency virus SIV-mac exist as homodimers. J. Virol. 64 (1990) 922-926
80. Ritter G.D., Yamshchikov G., Cohen S.J., and Mulligan M.J. Human immunodeficiency virus type 2 glycoprotein enhancement of particle budding: role of the cytoplasmic domain. J. Virol. 70 (1996) 2669-2673
81. Ryan-Graham M.A., and Peden K.W. Both virus and host components are important for the manifestation of a Nef-phenotype in HIV-1 and HIV-2. Virology 213 (1995) 158-168
82. Salvatori F., and Scarlatti G. HIV type 1 chemokine receptor usage in mother-to-child transmission. AIDS Res. Hum. Retroviruses 17 (2001) 925-935
83. Samson M., Libert F., Doranz B.J., Rucker J., Liesnard C., Farber C.M., Saragosti S., Lapoumeroulie C., Cognaux J., Forceille C., Muyldermans G., Verhofstede C., Burtonboy G., Georges M., Imai T., Rana S., Yi Y., Smyth R.J., Collman R.G., Doms R.W., Vassart G., and Parmentier M. Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 382 (1996) 722-725
84. Scarlatti G., Tresoldi E., Bjorndal A., Fredriksson R., Colognesi C., Deng H.K., Malnati M.S., Plebani A., Siccardi A.G., Littman D.R., Fenyo E.M., and Lusso P. In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression. Nat. Med. 3 (1997) 1259-1265
85. Schubert U., and Strebel K. Differential activities of the human immunodeficiency virus type 1-encoded Vpu protein are regulated by phosphorylation and occur in different cellular compartments. J. Virol. 68 (1994) 2260-2271
86. Simmons G., Reeves J.D., Hibbitts S., Stine J.T., Gray P.W., Proudfoot A.E., and Clapham P.R. Co-receptor use by HIV and inhibition of HIV infection by chemokine receptor ligands. Immunol. Rev. 177 (2000) 112-126
87. Simmons G., Wilkinson D., Reeves J.D., Dittmar M.T., Beddows S., Weber J., Carnegie G., Desselberger U., Gray P.W., Weiss R.A., and Clapham P.R. Primary, syncytium-inducing human immunodeficiency virus type 1 isolates are dual-tropic and most can use either Lestr or CCR5 as coreceptors for virus entry. J. Virol. 70 (1996) 8355-8360
88. Smyth R.J., Yi Y., Singh A., and Collman R.G. Determinants of entry cofactor utilization and tropism in a dualtropic human immunodeficiency virus type 1 primary isolate. J. Virol. 72 (1998) 4478-4484
89. Sol N., Ferchal F., Braun J., Pleskoff O., Treboute C., Ansart I., and Alizon M. Usage of the coreceptors CCR-5, CCR-3, and CXCR-4 by primary and cell line-adapted human immunodeficiency virus type 2. J. Virol. 71 (1997) 8237-8244
90. Srinivas S.K., Srinivas R.V., Anantharamaiah G.M., Segrest J.P., and Compans R.W. Membrane interactions of synthetic peptides corresponding to amphipathic helical segments of the human immunodeficiency virus type-1 envelope glycoprotein. J. Biol. Chem. 267 (1992) 7121-7127
91. Strebel K., Klimkait T., and Martin M.A. A novel gene of HIV-1, vpu, and its 16-kilodalton product. Science 241 (1988) 1221-1223
92. Tokiwa G., Dikic I., Lev S., and Schlessinger J. Activation of Pyk2 by stress signals and coupling with JNK signaling pathway. Science 273 (1996) 792-794
93. Venable R.M., Pastor R.W., Brooks B.R., and Carson F.W. Theoretically determined three-dimensional structures for amphipathic segments of the HIV-1 gp41 envelope protein. AIDS Res. Hum. Retroviruses 5 (1989) 7-22
94. Weissman D., Rabin R.L., Arthos J., Rubbert A., Dybul M., Swofford R., Venkatesan S., Farber J.M., and Fauci A.S. Macrophage-tropic HIV and SIV envelope proteins induce a signal through the CCR5 chemokine receptor. Nature 389 (1997) 981-985
95. Whittle H., Morris J., Todd J., Corrah T., Sabally S., Bangali J., Ngom P.T., Rolfe M., and Wilkins A. HIV-2-infected patients survive longer than HIV-1-infected patients. AIDS 8 (1994) 1617-1620
96. Zhang Y.J., Dragic T., Cao Y., Kostrikis L., Kwon D.S., Littman D.R., KewalRamani V.N., and Moore J.P. Use of coreceptors other than CCR5 by non-syncytium-inducing adult and pediatric isolates of human immunodeficiency virus type 1 is rare in vitro. J. Virol. 72 (1998) 9337-9344